Gastrointestinal stromal tumors: Definition, histological, immunohistochemical, and molecular features, and diagnostic strategy;Tumeurs stromales gastro-intestinales: Définition, caractéristiques histologiques, immunohistochimiques et génétiques, stratégie diagnostique

Annales de Pathologie

Volumn 25, Issue 5, 2005, Pages 358-385

  Coindre, Jean Michel ^a   Émile, Jean François ^b   Monges, Geneviève ^c   Ranchère Vince, Dominique ^d   Scoazec, Jean Yves ^e  

^a INSTITUT BERGONIÉ   (France)

^b HÔPITAL AMBROISE PARÉ   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d CENTRE LÉON BÉRARD   (France)

^e EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Digestive tumors; Gastrointestinal stromal tumors; GIST; Immunohistochemistry; KIT; Molecular pathology; Sarcomas

Indexed keywords

ALPHA ACTIN; CALDESMON; CD34 ANTIGEN; IMATINIB; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN S 100; STEM CELL FACTOR RECEPTOR;

CANCER CHEMOTHERAPY; CANCER RISK; CANCER SURGERY; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EPIDEMIOLOGICAL DATA; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNODETECTION; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOSARCOMA; LIPOSARCOMA; MESENCHYMOMA; MITOSIS INDEX; NEURILEMOMA; PROGNOSIS; REVIEW; RISK ASSESSMENT; SARCOMA; TREATMENT PLANNING; TUMOR CLASSIFICATION; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 32644488374     PISSN: 02426498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0242-6498(05)80145-2     Document Type: Short Survey

References (175)

1. Balaton AJ, Coindre JM, Cvitkovic F. Les tumeurs stromales gastro-intestinales. Gastroenterol Clin Biol 2001 ; 25 : 473-82.
2. Heinrich MC, Rubin BP, Longley BJ, Fletcher JA. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002 ; 33 : 484-95.
3. Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S et al. Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 2004 ; 43 : 3999-4006.
4. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004 ; 22 : 3813-25.
5. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002 ; 347 : 472-80.
6. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002 ; 33 : 459-65.
7. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005 ; 26 : 566-78.
8. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001 ; 438 : 1-12.
9. Miettinen M, Monihan JM, Sarlomo-Rikala M, Kovatich AJ, Carr NJ, Emory TS et al. Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery: clinicopathologic and immunohistochemical study of 26 cases. Am J Surg Pathol 1999 ; 23(9) : 1109-18.
10. Sakurai S, Hishima T, Takazawa Y, Sano T, Nakajima T, Saito K et al. Gastrointestinal stromal tumors and KIT-positive mesenchymal cells in the omentum. Pathol Int 2001 ; 51 : 524-31.
11. Hu X, Forster J, Damjanov I. Primary malignant gastrointestinal stromal tumor of the liver. Arch Pathol Lab Med 2003 ; 127 : 1606-8.
12. Yamaura K, Kato K, Miyazawa M, Haba Y, Muramatsu A, Miyata K et al. Stromal tumor of the pancreas with expression of c-kit protein: report of a case. J Gastroenterol Hepatol 2004 ; 19 : 467-70.
13. Daum O, Klecka J, Ferda J, Treska V, Vanecek T, Sima R et al. Gastrointestinal stromal tumor of the pancreas: case report with documentation of KIT gene mutation. Virchows Arch 2005 ; 11 : 470-2.
14. Sato O, Wada T, Kawai A, Yamaguchi U, Makimoto A, Kokai Y et al. Gastrointestinal stromal tumor of the pancreas: case report with documentation of KIT gene mutation. Cancer 2005 ; 446 : 470-2.
15. Miettinen M, Lasota J. KIT (CD117): A review on expression in normal and neoplastic tissues, and on mutations and their clinicopathologic correlations. Appl Immunohistochem Mol Morphol 2005 ; 13 : 205-20.
16. Debiec-Rychter M, Wasag B, Stul M, De Wever I, Van Oosterom A, Hagemeijer A et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 2004 ; 202 : 430-8.
17. Medeiros F, Corless CL, Duensing A, Hornick JL, Oliveira AM, Heinrich MC et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004 ; 28 : 889-94.
18. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998 ; 279 : 577-80.
19. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph N et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003 ; 299 : 708-10.
20. Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003 ; 125 : 660-7.
21. Antonescu CR, Viale A, Sarran L, Tschernyavsky SJ, Gonen M, Segal NH et al. Gastrointestinal stromal tumors: update. Clin Cancer Res 2004 ; 66 : 36-40.
22. Dei Tos AP. The reappraisal of gastrointestinal stromal tumors: from Stout to the KIT revolution. Virchows Arch 2003 ; 442 : 421-8.
23. Hjermstad BM, Sobin LH, Helwig EB. Stromal tumors of the gastrointestinal tract: myogenic or neurogenic? Am J Surg Pathol 1987 ; 41 : 383-6.
24. Pike AM, Lloyd RV, Appelman HD. Cell markers in gastrointestinal stromal tumors. Hum Pathol 1988 ; 19 : 830-4.
25. Miettinen M. Gastrointestinal stromal tumors. An immunohistochemical study of cellular differentiation. Am J Clin Pathol 1988 ; 106 : 601-10.
26. Ma CK, Amin MB, Kintanar E, Linden MD, Zarbo RJ. Immunohistologic characterization of gastrointestinal stromal tumors: a study of 82 cases compared with 11 cases of leiomyomas. Mod Pathol 1993 ; 6 : 139-44.
27. Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 1983 ; 68 : 507-19.
28. Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumours. Ann Chir Gynaecol 1998 ; 87 : 278-81.
29. Monihan JM, Carr NJ, Sobin LH. CD34 immunoexpression in stromal tumours of the gastrointestinal tract and in mesenteric fibromatoses. Histopathology 1994 ; 25 : 469-73.
30. Miettinen M, Virolainen M, Maarit Sarlomo R. Gastrointestinal stromal tumors - value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995 ; 19 : 207-16.
31. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998 ; 11(8) : 728-34.
32. Gibson PC, Cooper K. CD117 (KIT): a diverse protein with selective applications in surgical pathology. Adv Anat Pathol 2002 ; 9 : 65-9.
33. Duensing A, Heinrich MC, Fletcher CD, Fletcher JA. Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer Invest ; 22 : 106-16.
34. Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D et al. Gut pacemaker cells: the interstitial cells of Cajal (ICC). Am J Pathol 2003 ; 39: 137-61.
35. Lugli A, Went P, Khanlari B, Nikolova Z, Dirnhofer S. Interstitial cells in the musculature of the gastrointestinal tract: Cajal and beyond. Virchows Arch ; 229: 115-208.
36. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998 ; 152 : 1259-69.
37. Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I, Riddell RH. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 1999 ; 23 : 377-89.
38. Emile JF, Theou N, Tabone S, Cortez A, Terrier P, Chaumette MT et al. Clinicopathologic, phenotypic, and genotypic characteristics of gastrointestinal mesenchymal tumors. Clin Gastroenterol Hepatol 2004 ; 2 : 597-605.
39. Nilsson B, Bumming P, Meis-Kindblom JM, Oden A, Dortok A, Gustavsson B et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 2005 ; 103 : 821-9.
40. Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol 2002 ; 33 : 669-76.
41. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005 ; 100 : 162-8.
42. Tryggvason G, Gislason HG, Magnusson MK, Jonasson JG. Gastrointestinal stromal tumors in Iceland, 1990-2003: The Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005 ; 1/7 : 289-93.
43. Brun-Stang C, Bedossa P, Blay J-Y, J-M. C, Le Cesne A, Monges G et al. Les tumeurs stromales gastrointestinales : prévalence et incidence en France (résumé). Gastroenterol Clin Biol 2004 ; 28 : A206.
44. Cypriano MS, Jenkins JJ, Pappo AS, Rao BN, Daw NC. Pediatric gastrointestinal stromal tumors and leiomyosarcoma. Cancer 2004 ; 101 : 39-50.
45. Dijoud F, Frachon S, Basset T, Bertrand Y, Bergeron C. [Stromal gastrointestinal tumors in children: about a case]. Ann Pathol 2004 ; 130 : 628-31.
46. Rossi G, Valli R, Bertolini F, Marchioni A, Cavazza A, Mucciarini C et al. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. Histopathology 2005 ; 27 : 179-87.
47. Price VE, Zielenska M, Chilton-MacNeill S, Smith CR, Pappo AS. Clinical and molecular characteristics of pediatric gastrointestinal stromal tumors (GISTs). Pediatr Blood Cancer 2005 ; 4 : 20-4.
48. Bates AW, Feakins RM, Scheimberg I. Congenital gastrointestinal stromal tumour is morphologically indistinguishable from the adult form, but does not express CD117 and carries a favourable prognosis. Histopathology 2000 ; 37 : 316-22.
49. Nishida T, Hirota S, Taniguchi M, Hashimoto K, Isozaki K, Nakamura H et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet 1998 ; 19 : 323-4.
50. Isozaki K, Terris B, Belghiti J, Schiffmann S, Hirota S, Vanderwinden JM. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 2000 ; 157 : 1581-5.
51. Maeyama H, Hidaka E, Ota H, Minami S, Kajiyama M, Kuraishi A et al. Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001 ; 120 : 210-5.
52. Chen H, Hirota S, Isozaki K, Sun H, Ohashi A, Kinoshita K et al. Polyclonal nature of diffuse proliferation of interstitial cells of Cajal in patients with familial and multiple gastrointestinal stromal tumours. Gut 2002 ; 51 : 793-6.
53. Hirota S, Nishida T, Isozaki K, Taniguchi M, Nishikawa K, Ohashi A et al. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology 2002 ; 122 : 1493-9.
54. Chompret A, Kannengiesser C, Barrois M, Terrier P, Dahan P, Tursz T et al. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor. Gastroenterology 2004 ; 202 : 318-21.
55. Carballo M, Roig I, Aguilar F, Pol MA, Gamundi MJ, Hernan I et al. Novel c-KIT germline mutation in a family with gastrointestinal stromal tumors and cutaneous hyperpigmentation. Am J Med Genet A 2005 ; 11 : 361-4.
56. Li FP, Fletcher JA, Heinrich MC, Garber JE, Sallan SE, Curiel-Lewandrowski C et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol 2005 ; : 2735-43.
57. Prakash S, Sarran L, Socci N, DeMatteo RP, Eisenstat J, Greco AM et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Pediatr Hematol Oncol 2005 ; 23 : 2735-43.
58. Schaldenbrand JD, Appelman HD. Solitary solid stromal gastrointestinal tumors in von Recklinghausen's disease with minimal smooth muscle differentiation. Hum Pathol 1984 ; 19 : 229-32.
59. Andersson J, Sihto H, Meis-Kindblom JM, Joensuu H, Nupponen N, Kindblom LG. NF1-Associated Gastrointestinal Stromal Tumors Have Unique Clinical, Phenotypic, and Genotypic Characteristics. Am J Surg Pathol 2005 ; 29 : 1170-6.
60. Takazawa Y, Sakurai S, Sakuma Y, Ikeda T, Yamaguchi J, Hashizume Y et al. Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen's disease). Am J Surg Pathol 2005 ; 11 : 755-63.
61. Yantiss RK, Rosenberg AE, Sarran L, Besmer P, Antonescu CR. Multiple gastrointestinal stromal tumors in type I neurofibromatosis: a pathologic and molecular study. Mod Pathol 2005 ; 18 : 475-84.
62. Min KW. Small intestinal stromal tumors with skeinoid fibers. Clinicopathological, immunohistochemical, and ultrastructural investigations. Am J Surg Pathol 1992 ; 16 : 145-55.
63. Went PT, Dirnhofer S, Bundi M, Mirlacher M, Schraml P, Mangialaio S et al. Prevalence of KIT expression in human tumors. J Clin Oncol 2004 ; 22 : 4514-22.
64. Fletcher CD, Fletcher JA. Testing for KIT (CD117) in gastrointestinal stromal tumors: another Hercep-Test? Appl Immunohistochem Mol Morphol 2002 ; 10 : 197-8.
65. Hornick JL, Fletcher CD. Validating immunohistochemical staining for KIT (CD117). Am J Clin Pathol 2003 ; 119 : 325-7.
66. Berman J, O'Leary TJ. Gastrointestinal stromal tumor workshop. Hum Pathol 2001 ; 32 : 578-82.
67. Rudolph P, Chiaravalli AM, Pauser U, Oschlies I, Hillemanns M, Gobbo M et al. Gastrointestinal mesenchymal tumors - immunophenotypic classification and survival analysis. Virchows Arch 2002 ; 441: 238-48.
68. Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom AT, Sciot R. Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall. Histopathology 2005 ; 58 : 41-7.
69. Hornick JL, Fletcher CD. Immunohistochemical staining for KIT (CD117) in soft tissue sarcomas is very limited in distribution. Am J Clin Pathol 2002 ; 117 : 188-93.
70. Miettinen M. Are desmoid tumors kit positive? Am J Surg Pathol 2001 ; 25 : 549-50.
71. Miettinen M, Sarlomo-Rikala M, Lasota J. KIT expression in angiosarcomas and fetal endothelial cells: lack of mutations of exon 11 and exon 17 of C-kit. Mod Pathol 2000 ; 13 : 536-41.
72. Sabah M, Leader M, Kay E. The problem with KIT: clinical implications and practical difficulties with CD117 immunostaining. Appl Immunohistochem Mol Morphol 2003 ; 11: 56-61.
73. Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004 ; 164 : 305-13.
74. Taniere P, Poncet G, Atieh R, Saurin JC, Henry L, Scoazec JY. Toutes les tumeurs digestives exprimant la protéine c-kit ne sont pas des tumeurs stromales. Gastroenterol Clin Biol 2002 ; 26 : 1057.
75. Arber DA, Tamayo R, Weiss LM. Paraffin section detection of the c-kit gene product (CD117) in human tissues: value in the diagnosis of mast cell disorders. Hum Pathol 1998 ; 29 : 498-504.
76. Butnor KJ, Burchette JL, Sporn TA, Hammar SP, Roggli VL. The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature. Arch Pathol Lab Med 2004 ; 128 : 538-43.
77. Pan CC, Chen PC. A distinct expression pattern and point mutation of c-KIT in papillary renal cell carcinomas. Mod Pathol 2004 ; 17 : 1440-1; author reply 2-4.
78. Pan CC, Chen PC, Chiang H. Overexpression of KIT (CD117) in chromophobe renal cell carcinoma and renal oncocytoma. Am J Clin Pathol 2004 ; 121 : 878-83.
79. Petit A, Castillo M, Santos M, Mellado B, Alcover JB, Mallofre C. KIT expression in chromophobe renal cell carcinoma: comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms. Am J Surg Pathol 2004 ; 28 : 676-8.
80. Pan CC, Chen PC, Chiang H. KIT (CD117) is frequently overexpressed in thymic carcinomas but is absent in thymomas. J Pathol 2004 ; 202 : 375-81.
81. Tse GM, Putti TC, Lui PC, Lo AW, Scolyer RA, Law BK et al. Increased c-kit (CD117) expression in malignant mammary phyllodes tumors. Mod Pathol 2004 ; 128 : 827-31.
82. Jeng YM, Lin CY, Hsu HC. Expression of the c-kit protein is associated with certain subtypes of salivary gland carcinoma. Cancer Lett 2000 ; 154 : 107-11.
83. Kinoshita K, Hirota S, Isozaki K, Ohashi A, Nishida T, Kitamura Y et al. Expression of KIT (CD117) in neoplasms of the head and neck: an ancillary marker for adenoid cystic carcinoma. J Pathol 2003 ; 16 : 1224-31.
84. Penner CR, Folpe AL, Budnick SD. C-kit expression distinguishes salivary gland adenoid cystic carcinoma from polymorphous low-grade adenocarcinoma. Mod Pathol 2002; 15 : 687-91.
85. Sommer G, Agosti V, Ehlers I, Rossi F, Corbacioglu S, Farkas J et al. C-kit expression in the salivary gland neoplasms adenoid cystic carcinoma, polymorphous low-grade adenocarcinoma, and monomorphic adenoma. Proc Natl Acad Sci U S A 2003 ; 95 : 586-93.
86. Hervieu V, Terdjman P, Scoazec JY. c-kit: parfois un faux ami ! Ann Pathol 2003 ; 23 : 189-90.
87. Martland GT, Goodman AJ, Shepherd NA. CD117 expression in oesophageal carcinosarcoma: a potential diagnostic pitfall. Histopathology 2004 ; 44 : 77-80.
88. Menczer J, Kravtsov V, Levy T, Berger E, Glezerman M, Avinoach I. Expression of c-kit in uterine carcinosarcoma. Gynecol Oncol 2005 ; 96 : 210-5.
89. Ahmed A, Gilbert-Barness E, Lacson A. Expression of c-kit in Ewing family of tumors: a comparison of different immunohistochemical protocols. Pediatr Dev Pathol 2004; 7 : 342-7.
90. Lucas DR, al-Abbadi M, Tabaczka P, Hamre MR, Weaver DW, Mott MJ. c-Kit expression in desmoid fibromatosis. Comparative immunohistochemical evaluation of two commercial antibodies. Am J Clin Pathol 2003 ; 119 : 339-45.
91. Rodriguez JA, Guarda LA, Rosai J. Mesenteric fibromatosis with involvement of the gastrointestinal tract. A GIST simulator: a study of 25 cases. Am J Clin Pathol 2004 ; 34 : 93-8.
92. Yantiss RK, Spiro IJ, Compton CC, Rosenberg AE. Gastrointestinal stromal tumor versus intra-abdominal fibromatosis of the bowel wall: a clinically important differential diagnosis. Am J Surg Pathol 2000 ; 24 : 947-57.
93. Miettinen M, Lindenmayer AE, Chaubal A. Endothelial cell markers CD31, CD34, and BNH9 antibody to H- and Y-antigens - evaluation of their specificity and sensitivity in the diagnosis of vascular tumors and comparison with von Willebrand factor. Mod Pathol 1994; 7 : 82-90.
94. van de Rijn M, Hendrickson MR, Rouse RV. CD34 expression by gastrointestinal tract stromal tumors. Hum Pathol 1994; 25 : 766-71.
95. West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004 ; 165 : 107-13.
96. Blay P, Astudillo A, Buesa JM, Campo E, Abad M, Garcia-Garcia J et al. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res 2004 ; 10 : 4089-95.
97. Duensing A, Joseph NE, Medeiros F, Smith F, Hornick JL, Heinrich MC et al. Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res 2004 ; 64 : 5127-31.
98. Motegi A, Sakurai S, Nakayama H, Sano T, Oyama T, Nakajima T. PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors. Pathol Int 2005 ; 132 : 106-12.
99. Miettinen MM, Sarlomo-Rikala M, Kovatich AJ, Lasota J. Calponin and h-caldesmon in soft tissue tumors: consistent h-caldesmon immunoreactivity in gastrointestinal stromal tumors indicates traits of smooth muscle differentiation. Mod Pathol 1999 ; 12 : 756-62.
100. Sarlomo-Rikala M, Tsujimura T, Lendahl U, Miettinen M. Patterns of nestin and other intermediate filament expression distinguish between gastrointestinal stromal tumors, leiomyomas and schwannomas. APMIS 2002 ; 110 : 499-507.
101. Seidal T, Edvardsson H. Expression of c-kit (CD117) and Ki67 provides information about the possible cell of origin and clinical course of gastrointestinal stromal tumours. Histopathology 1999 ; 34 : 416-24.
102. Panizo-Santos A, Sola I, Vega F, de Alava E, Lozano MD, Idoate MA et al. Predicting Metastatic Risk of Gastrointestinal Stromal Tumors: Role of Cell Proliferation and Cell Cycle Regulatory Proteins. Int J Surg Pathol 2000 ; 8 : 133-44.
103. Wong NA, Young R, Malcomson RD, Nayar AG, Jamieson LA, Save VE et al. Prognostic indicators for gastrointestinal stromal tumours: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology 2003 ; 43 : 118-26.
104. Miettinen M, El-Rifai W, Sobin L, Lasota J. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 2002 ; 33 : 478-83.
105. Schneider-Stock R, Boltze C, Lasota J, Miettinen M, Peters B, Pross M et al. High prognostic value of p16INK4 alterations in gastrointestinal stromal tumors. J Clin Oncol 2003 ; 21 : 1688-97.
106. Sabah M, Cummins R, Leader M, Kay E. Loss of heterozygosity of chromosome 9p and loss of p16INK4A expression are associated with malignant gastrointestinal stromal tumors. Mod Pathol 2004 ; 17 : 1364-71.
107. Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless CL, Ruemmele P et al. Loss of p16 protein defines high-risk patients with gastrointestinal stromal tumors: a tissue microarray study. Clin Cancer Res 2005 ; 11 : 638-45.
108. Ricci R, Maggiano N, Castri F, Rinelli A, Murazio M, Pacelli F et al. Role of PTEN in gastrointestinal stromal tumor progression. Arch Pathol Lab Med 2004 ; 28 : 421-5.
109. Montgomery E, Abraham SC, Fisher C, Deasel MR, Amr SS, Sheikh SS et al. CD44 loss in gastric stromal tumors as a prognostic marker. Am J Surg Pathol 2004 ; 21 : 168-77.
110. Moskaluk CA, Tian Q, Marshall CR, Rumpel CA, Franquemont DW, Frierson HF, Jr. Mutations of c-kit JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene 1999 ; 18(10) : 1897-902.
111. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001 ; 61 : 8118-21.
112. Ernst SI, Hubbs AE, Przygodzki RM, Emory TS, Sobin LH, TJ OL. KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest 1998 ; 78 : 1633-6.
113. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 1999 ; 154(1) : 53-60.
114. Sakurai S, Fukasawa T, Chong JM, Tanaka A, Fukayama M. C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of Cajal). Jpn J Cancer Res 1999 ; 90 : 1321-8.
115. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999 ; 59(17) : 4297-300.
116. Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol 2000 ; 24 : 1339-52.
117. Miettinen M, Sarlomo-Rikala M, Sobin LH, Lasota J. Esophageal stromal tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas. Am J Surg Pathol 2000 ; 24 : 211-22.
118. Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin LH, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol 2001 ; 25 : 1121-33.
119. Miettinen M, Kopczynski J, Makhlouf HR, Sarlomo-Rikala M, Gyorffy H, Burke A et al. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol 2003 ; 27 : 625-41.
120. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005 ; 29 : 52-68.
121. Andersson J, Sjogren H, Meis-Kindblom JM, Stenman G, Aman P, Kindblom LG. The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 2002 ; 160 : 15-22.
122. Feng F, Liu XH, Xie Q, Liu WQ, Bai CG, Ma DL. Expression and mutation of c-kit gene in gastrointestinal stromal tumors. World J Gastroenterol 2003 ; 9 : 2548-51.
123. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003 ; 21 : 4342-9.
124. Antonescu CR, Sommer G, Sarran L, Tschernyavsky SJ, Riedel E, Woodruff JM et al. Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003 ; 9 : 3329-37.
125. Wardelmann E, Losen I, Hans V, Neidt I, Speidel N, Bierhoff L et al. Deletion of Trp-557 and Lys-558 in the juxtamembrane domain of the c-kit protooncogene is associated with metastatic behavior of gastrointestinal stromal tumors. Int J Cancer 2003 ; : 887-95.
126. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2004 ; 40 : 689-95.
127. Lasota J, Wozniak A, Sarlomo-Rikala M, Rys J, Kordek R, Nassar A et al. Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. A study of 200 cases. Am J Pathol 2000 ; 157 : 1091-5.
128. Sakurai S, Oguni S, Hironaka M, Fukayama M, Morinaga S, Saito K. Mutations in c-kit gene exons 9 and 13 in gastrointestinal stromal tumors among Japanese. Jpn J Cancer Res 2001 ; 92 : 494-8.
129. Kinoshita K, Isozaki K, Hirota S, Nishida T, Chen H, Nakahara M et al. c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol Hepatol 2003 ; 18 : 147-51.
130. Lasota J, Dansonka-Mieszkowska A, Stachura T, Schneider-Stock R, Kallajoki M, Steigen SE et al. Gastrointestinal stromal tumors with internal tandem duplications in 3' end of KIT juxtamembrane domain occur predominantly in stomach and generally seem to have a favorable course. Mod Pathol 2003 ; 16 : 1257-64.
131. Sakurai S, Hasegawa T, Sakuma Y, Takazawa Y, Motegi A, Nakajima T et al. Myxoid epithelioid gastrointestinal stromal tumor (GIST) with mast cell infiltrations: a subtype of GIST with mutations of platelet-derived growth factor receptor alpha gene. Hum Pathol 2004 ; 35 : 1223-30.
132. Lasota J, Kopczynski J, Sarlomo-Rikala M, Schneider-Stock R, Stachura T, Kordek R et al. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal origin. Hum Pathol 2003 ; 34 : 1306-12.
133. Lasota J, Dansonka-Mieszkowska A, Sobin LH, Miettinen M. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 2004 ; 84 : 874-83.
134. Emile JF, Lemoine A, Bienfait N, Terrier P, Azoulay D, Debuire B. Length analysis of polymerase chain reaction products: a sensitive and reliable technique for the detection of mutations in KIT exon 11 in gastrointestinal stromal tumors. Diagn Mol Pathol 2002 ; 11 : 107-12.
135. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002 ; 160 : 1567-72.
136. Joensuu H, Roberts PJ, Sarlomo-Rikala M. Effect of the tyrosine inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001 ; 344 : 1052-6.
137. El-Rifai W, Sarlomo-Rikala M, Miettinen M, Knuutila S, Andersson LC. DNA copy number losses in chromosome 14: an early change in gastrointestinal stromal tumors. Cancer Res 1996 ; 56 : 3230-3.
138. Breiner JA, Meis-Kindblom J, Kindblom LG, McComb E, Liu J, Nelson M et al. Loss of 14q and 22q in gastrointestinal stromal tumors (pacemaker cell tumors). Cancer Genet Cytogenet 2000 ; 120 : 111-6.
139. El-Rifai W, Sarlomo-Rikala M, Andersson LC, Miettinen M, Knuutila S. High-resolution deletion mapping of chromosome 14 in stromal tumors of the gastrointestinal tract suggests two distinct tumor suppressor loci. Genes Chromosomes Cancer 2000 ; 27 : 387-91.
140. Fukasawa T, Chong JM, Sakurai S, Koshiishi N, Ikeno R, Tanaka A et al. Allelic loss of 14q and 22q, NF2 mutation, and genetic instability occur independently of c-kit mutation in gastrointestinal stromal tumor. Jpn J Cancer Res 2000 ; 91 : 1241-9.
141. Debiec-Rychter M, Sciot R, Pauwels P, Schoenmakers E, Dal Cin P, Hagemeijer A. Molecular cytogenetic definition of three distinct chromosome arm 14q deletion intervals in gastrointestinal stromal tumors. Genes Chromosomes Cancer 2001 ; 32 : 26-32.
142. Knuutila S, Armengol G, Bjorkqvist AM, el-Rifai W, Larramendy ML, Monni O et al. Comparative genomic hybridization study on pooled DNAs from tumors of one clinical-pathological entity. Cancer Genet Cytogenet 1998 ; 100 : 25-30.
143. Debiec-Rychter M, Pauwels P, Lasota J, Franke S, De Vos R, De Wever I et al. Complex genetic alterations in gastrointestinal stromal tumors with autonomic nerve differentiation. Mod Pathol 2002 ; 15 : 692-8.
144. Allander SV, Nupponen NN, Ringner M, Hostetter G, Maher GW, Goldberger N et al. Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile. Cancer Res 2001 ; 61 : 8624-8.
145. Antonescu CR, Viale A, Sarran L, Tschernyavsky SJ, Gonen M, Segal NH et al. Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 2004 ; 10 : 3282-90.
146. Subramanian S, West RB, Corless CL, Ou W, Rubin BP, Chu KM et al. Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles. Oncogene 2004 ; 23 : 7780-90.
147. Kang HJ, Nam SW, Kim H, Rhee H, Kim NG, Kim H et al. Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene 2005 ; 24 : 1066-74.
148. Grate LR, Bhattacharyya C, Jordan MI, Mian IS. Integrated analysis of transcript profiling and protein sequence data. Mech Ageing Dev 2003 ; 124 : 109-14.
149. Tornillo L, Duchini G, Carafa V, Lugli A, Dirnhofer S, Di Vizio D et al. Patterns of gene amplification in gastrointestinal stromal tumors (GIST). Lab Invest 2005 ; 54 : 921-31.
150. Seremetis MG, Lyons WS, deGuzman VC, Peabody JW Jr. Leiomyomata of the esophagus. An analysis of 838 cases. Cancer 1976 ; 38 : 2166-77.
151. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000 ; 13 : 1134-42.
152. Daimaru Y, Kido H, Hashimoto H, Enjoji M. Benign schwannoma of the gastrointestinal tract: a clinicopathologic and immunohistochemical study. Hum Pathol 1988 ; 19 : 257-64.
153. Sarlomo-Rikala M, Miettinen M. Gastric schwannoma a clinicopathological analysis of six cases. Histopathology 1995 ; 27 : 355-60.
154. Miettinen M, Shekitka KM, Sobin LH. Schwannomas in the colon and rectum: a clinicopathologic and immunohistochemical study of 20 cases. Am J Surg Pathol 2001 ; 25 : 846-55.
155. Kwon MS, Lee SS, Ahn GH. Schwannomas of the gastrointestinal tract: clinicopathological features of 12 cases including a case of esophageal tumor compared with those of gastrointestinal stromal tumors and leiomyomas of the gastrointestinal tract. Pathol Res Pract 2002 ; 198 : 605-13.
156. Burke AP, Sobin LH, Shekitka KM, Federspiel BH, Helwig EB. Intra-abdominal fibromatosis. A pathologic analysis of 130 tumors with comparison of clinical subgroups. Am J Surg Pathol 1990 ; 14 : 335-41.
157. Hasegawa T, Yang P, Kagawa N, Hirose T, Sano T. CD34 expression by inflammatory fibroid polyps of the stomach. Mod Pathol 1997 ; 10 : 451-6.
158. Pantanowitz L, Antonioli DA, Pinkus GS, Shahsafaei A, Odze RD. Inflammatory fibroid polyps of the gastrointestinal tract: evidence for a dendritic cell origin. Am J Surg Pathol 2004 ; 28 : 107-14.
159. Coffin CM, Dehner LP, Meis-Kindblom JM. Inflammatory myofibroblastic tumor, inflammatory fibrosarcoma, and related lesions: an historical review with differential diagnostic considerations. Semin Diagn Pathol 1998 ; 15 : 102-10.
160. Shidham VB, Chivukula M, Gupta D, Rao RN, Komorowski R. Immunohistochemical comparison of gastrointestinal stromal tumor and solitary fibrous tumor. Arch Pathol Lab Med 2002 ; 126 : 1189-92.
161. Miettinen M, Paal E, Lasota J, Sobin LH. Gastrointestinal glomus tumors: a clinicopathologic, immunohistochemical, and molecular genetic study of 32 cases. Am J Surg Pathol 2002 ; 26 : 301-11.
162. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000 ; 231 : 51-8.
163. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002 ; 33 : 466-77.
164. Aparicio T, Boige V, Sabourin JC, Crenn P, Ducreux M, Le Cesne A et al. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumours. Eur J Surg Oncol 2004 ; 30 : 1098-103.
165. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002 ; 20 : 3898-905.
166. Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002 ; 38 Suppl 5 : S39-51.
167. Emory TS, Sobin LH, Lukes L. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999 ; 23 : 82-7.
168. Penzel R, Aulmann S, Moock M, Schwarzbach M, Rieker RJ, Mechtersheimer G. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated. J Clin Pathol 2005 ; 57 : 634-9.
169. Wasag B, Debiec-Rychter M, Pauwels P, Stul M, Vranckx H, Oosterom AV et al. Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site. Mod Pathol 2004 ; 17 : 889-94.
170. Wardelmann E, Hrychyk A, Merkelbach-Bruse S, Pauls K, Goldstein J, Hohenberger P et al. Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn 2004 ; 6 : 197-204.
171. Blay JY, Le Cesne A, Alberti L, Ray-Coquart I. Targeted cancer therapies. Bull Cancer 2005 ; 9 : E13-8.
172. Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg. Eur J Cancer 2005 ; 41 : 1751-7.
173. Chen LL, Sabripour M, Andtbacka RH, Patel SR, Feig BW, Macapinlac HA et al. Imatinib resistance in gastrointestinal stromal tumors. Curr Oncol Rep 2005 ; 20 : 293-9.
174. Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005 ; 128 : 270-9.
175. Robson ME, Glogowski E, Sommer G, Antonescu CR, Nafa K, Maki RG et al. Molecular response of gastrointestinal stromal tumour after treatment with tyrosine kinase inhibitor imatinib mesylate. Clin Cancer Res 2004 ; 57 : 215-7.